COMMUNIQUÉS West-GlobeNewswire

Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Parkinson’s Disease Patients with a GBA1 Mutation
08/07/2019
Company Plans to Initiate Phase 1/2 Clinical Trial in the Second Half of 2019 NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (Prevail), a biotechnology company developing [...]
Gritstone Oncology Announces the Appointment of Dr. Vijay Yabannavar, a Biopharma Leader with Over 30 Years of Experience, as Executive Vice President of Manufacturing and Technical Operations
08/07/2019
EMERYVILLE, Calif., July 08, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer [...]
Bellicum Pharmaceuticals Announces Rivo-cel™ Achieves Primary Endpoint in Pediatric Registrational Trial
08/07/2019
Primary endpoint of event free survival (EFS) rate at 180 days of 90.9 percent reported for rivo‑cel in BP-004 European registrational trial Investigational trial results support potential that haploidentical stem cell [...]
Adverum Biotechnologies to Present Data at Upcoming Conferences
08/07/2019
-- OPTIC Phase 1 Data for ADVM-022 in Wet AMD for First Cohort to be Presented at Retina Society Annual Meeting in September 2019 -- MENLO PARK, Calif., July 08, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. ( [...]
James Green Named President and CEO of Harvard Bioscience
08/07/2019
HOLLISTON, Mass., July 08, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that James Green has been named President and Chief Executive Officer of the Company by its Board of Directors [...]
SIGA Awarded Department of Defense Contract to Develop Expanded Indication for TPOXX® as Post-Exposure Prophylactic for Smallpox
08/07/2019
NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has been awarded a [...]
Progenics Pharmaceuticals Strengthens Management Team with Appointment of Huw Jones as Vice President, Commercial
08/07/2019
-Commercial Leader Brings Deep Experience in Radiopharmaceuticals and Oncology- NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative [...]
Aravive Announces Independent Data Monitoring Committee Recommends Continuation of Phase Ib Study of AVB-500 In Recurrent Platinum Resistant Ovarian Cancer After Review of First Two Cohorts of Patients
08/07/2019
AVB-500 demonstrates favorable safety profile and full suppression of circulating GAS6 in cancer patients HOUSTON, July 08, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Aravive) (NASDAQ:ARAV), a clinical-stage [...]
Sol-Gel Announces Positive Top-Line Results from Epsolay® Phase 3 Program in Papulopustular Rosacea
08/07/2019
All primary and secondary endpoints achieved in both Phase 3 clinical trials Rapid efficacy demonstrated, with statistical significance reached as early as Week 2 compared with vehicle Favorable safety and tolerability [...]
Share buy-back week 27/2019
08/07/2019
Announcement 8 July 2019 Coloplast – transactions in connection with share buy-back programme As mentioned in Announcement No. 2/2019 Coloplast has initiated the second part of the share buy-back programme totalling up [...]
Intra-Cellular Therapies Announces Positive Top-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression
08/07/2019
Study 404 met its primary endpoint of change from baseline at Week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score versus placebo (p<0.001; effect size = 0.56). Study 404 also met its key [...]
Batavia Biosciences receives $2.2 million follow-up grant from PATH to support new tools for polio eradication era
08/07/2019
Leiden, 4 Jul 2019 – Today, Batavia Biosciences announces it received a follow-up grant of $2.2 million from PATH – a global organization dedicated to health equity – to develop and manufacture novel oral poliovirus [...]
Inspire Medical Systems, Inc. Announces UnitedHealthcare Coverage for Inspire Therapy for the Treatment of Obstructive Sleep Apnea
08/07/2019
MINNEAPOLIS, July 08, 2019 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (the “Company” or “Inspire”), a medical technology company focused on the development and commercialization of innovative and [...]
Newly Published Nicotinamide Riboside Study Further Demonstrates Safety of Sustained Niagen Supplementation and Optimal Dosing Levels
08/07/2019
New clinical study shows Niagen® supplementation safe and effective at the recommended daily serving; statistically significant sustained blood NAD+ levels LOS ANGELES, July 08, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp [...]
Transactions under Novozymes’ stock buyback program
08/07/2019
Please read the full announcement in the attached PDF Attachment 2019_22_Stock_Buybackprogram_EN
NoorLine lance un site Web à visée thérapeutique adapté à chaque culture et disponible 24 h/24 gratuitement
08/07/2019
DÉTROIT (États-Unis), 08 juill. 2019 (GLOBE NEWSWIRE) -- NoorLine, une ligne d'écoute anonyme et gratuite, a été lancée à Détroit cette semaine pour proposer un soutien moral anonyme par des pairs 24 h/24 aux personnes [...]
Catalyst Biosciences Meets the Primary Endpoint of Reduction in Annualized Bleeding Rate in the Phase 2 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Patients with Hemophilia A or B with Inhibitors
08/07/2019
Subcutaneous MarzAA (FVIIa) prophylaxis reduced the annualized bleeding rate by more than 90% compared with pretreatment Data presented at the 2019 Congress of the International Society on Thrombosis and Haemostasis [...]
AB Science announces the publication of the positive phase 2/3 clinical trial with masitinib in ALS in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
08/07/2019
Paris, 8 th July 2019, 7.30am Publication of the positive phase 2/3 clinical trial with masitinib in ALS in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration AB Science SA (NYSE Euronext - [...]
AB Science annonce la publication de l’étude positive de phase 2/3 du masitinib dans la SLA dans la revue Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
08/07/2019
Paris, 8 juillet 2019, 7h30 Publication de l’étude positive de phase 2/3 du masitinib dans la SLA dans la revue Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration AB Science SA (NYSE Euronext - FR0010557264 [...]

Pages